WallStreetZenWallStreetZen

NASDAQ: EVGN
Evogene Ltd Stock Forecast, Predictions & Price Target

Analyst price target for EVGN

Based on 1 analyst offering 12 month price targets for Evogene Ltd.
Min Forecast
$1.85+151.7%
Avg Forecast
$1.85+151.7%
Max Forecast
$1.85+151.7%

Should I buy or sell EVGN stock?

Based on 1 analyst offering ratings for Evogene Ltd.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EVGN stock forecasts and price targets.

EVGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-10-02

1 of 1

Forecast return on equity

Is EVGN forecast to generate an efficient return?
Company
-138.5%
Industry
7.6%
Market
29.39%
EVGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EVGN forecast to generate an efficient return on assets?
Company
-32.67%
Industry
9.48%
EVGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EVGN revenue forecast

What is EVGN's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$34.9M+519.33%
EVGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EVGN revenue growth forecast

How is EVGN forecast to perform vs Biotechnology companies and vs the US market?
Company
519.33%
Industry
230.34%
Market
13.87%
EVGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EVGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EVGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EVGN$0.74$1.85+151.70%Strong Buy
SER$14.87N/AN/A
ACXP$2.33$12.00+415.02%Buy
PLUR$0.88N/AN/A
OKYO$1.50$7.00+366.67%Buy

Evogene Stock Forecast FAQ

Is Evogene Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: EVGN) stock is to Strong Buy EVGN stock.

Out of 1 analyst, 1 (100%) are recommending EVGN as a Strong Buy, 0 (0%) are recommending EVGN as a Buy, 0 (0%) are recommending EVGN as a Hold, 0 (0%) are recommending EVGN as a Sell, and 0 (0%) are recommending EVGN as a Strong Sell.

If you're new to stock investing, here's how to buy Evogene stock.

What is EVGN's revenue growth forecast for 2024-2024?

(NASDAQ: EVGN) Evogene's forecast annual revenue growth rate of 519.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 230.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.87%.

Evogene's revenue in 2024 is $5,640,000.

In 2024, EVGN is forecast to generate $1,766,930,138 in revenue, with the lowest revenue forecast at $1,766,930,138 and the highest revenue forecast at $1,766,930,138.

What is EVGN's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: EVGN) forecast ROA is -32.67%, which is lower than the forecast US Biotechnology industry average of 9.48%.

What is EVGN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EVGN price target, the average EVGN price target is $1.85, with the highest EVGN stock price forecast at $1.85 and the lowest EVGN stock price forecast at $1.85.

The Wall Street analyst predicted that Evogene's share price could reach $1.85 by Oct 2, 2024. The average Evogene stock price prediction forecasts a potential upside of 151.7% from the current EVGN share price of $0.74.

What is EVGN's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: EVGN) forecast ROE is -138.5%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.